SCHEMBL30206107

SCHEMBL30206107

CNc1nc(Nc2ccccc2)c(C(=O)OC)nc1-c1cncc2c1ncn2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ ALOX15 P16050 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ CSNK2A1 P68400 2/20 0.34
▸ SRC P12931 1/20 0.33
▸ MAP4K1 Q92918 1/20 0.33
▸ CDK2 P24941 2/20 0.33
▸ PLK1 P53350 2/20 0.33
▸ IKBKB O14920 1/20 0.33
▸ CHUK O15111 1/20 0.33
▸ BTK Q06187 1/20 0.33
▸ ITK Q08881 1/20 0.33
▸ IKBKE Q14164 1/20 0.33
▸ ADORA3 P0DMS8 2/20 0.32
▸ ADORA2A P29274 2/20 0.32
▸ ADORA1 P30542 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173378 1.00 CYP1A2 (0.35) CYP1A2CYP3A4ALOX15HSD17B10LMNA
SCHEMBL24943828 0.90 CDK2 (0.37) CSNK2A1MAP4K1CDK2PLK1IKBKB
SCHEMBL30206336 0.89 SYK (0.36) LMNABTKMAPTALDH1A1KMT2A
SCHEMBL29173448 0.89 SYK (0.36) LMNABTKMAPTALDH1A1KMT2A
SCHEMBL30206265 0.89 BTK (0.34) BTK
SCHEMBL29173474 0.88 HPGD (0.32) YTHDC1
SCHEMBL29173406 0.88 CDK2 (0.33) CYP1A2CYP3A4ALOX15HSD17B10CSNK2A1
SCHEMBL30205968 0.88 HPGD (0.32) YTHDC1
SCHEMBL30206114 0.87 BTK (0.30) BTK
SCHEMBL29173540 0.87 SYK (0.36) BTKITKCDK4CCND3LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 CYP1A2 2440/4885CYP3A4 2906/4885ALOX15 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback